Cabergoline |
Last updated: 18/05/2024 |
(Not known by any other names) |
|
|
An ergot derivative which is a prolactin Inhibitor/dopamine (D2) agonist used to reduce prolactin levels in veterinary medicine | |
---|---|---|
|
Current | |
|
1981, developed Italy | |
|
Drug used to suppress lactation and treat phantom pregnancy as well as to induce estrus (heat), and treat anestrus (no estrus) & canine mastitis. | |
|
Dogs; Cats |
Approval status |
|
Approved | |
---|---|---|
|
Approved |
Chemical structure |
|
Isomeric | |
---|---|---|
|
C₂₆H₃₇N₅O₂ | |
|
CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C | |
|
CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C | |
|
KORNTPPJEAJQIU-KJXAQDMKSA-N | |
|
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 | |
|
Yes |
|
Common Name | Relationship | Link |
---|---|---|
cabergoline | - |
General status |
|
Gynecological drug, Medicinal drug | |
---|---|---|
|
Ergot derivative | |
|
98% | |
|
- | |
|
Synthetic | |
|
A dopamine D2 receptor agonist; a potent prolactin inhibitor. | |
|
[D(2) dopamine receptor, Agonist], [5-hydroxytryptamine 2B receptor, agonist], [D(3) dopamine receptor, agonist], [5-hydroxytryptamine 2A receptor, agonist], [Alpha-2B adrenergic receptor, Antagonist], [5-hydroxytryptamine 1D receptor, agonist], [Alpha-2A adrenergic receptor, Antagonist], [5-hydroxytryptamine 1A receptor, agonist], [Alpha-2C adrenergic receptor, Antagonist], [D(1B) dopamine receptor, agonist], [D(1A) dopamine receptor, agonist], [5-hydroxytryptamine 1B receptor, agonist], [5-hydroxytryptamine 2C receptor, agonist], [5-hydroxytryptamine 7 receptor, Antagonist] | |
|
81409-90-7 | |
|
- | |
|
- | |
|
- | |
|
54746 | |
|
Genito urinary system & sex hormones: Other gynecologicals | |
|
QG02CB03 | |
|
No | |
|
- | |
|
451.60 | |
|
- | |
|
N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]- 6-(2-propenyl)-8g-ergoline-8-carboxamide | |
|
- | |
|
- | |
|
- | |
|
White powder |
Formulations |
|
|
|
|
|
||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Galastop 50 µg/ml Oral solution | Ceva Salute Animale S.p.A. | UK National authorisation | Prescription only medicine to be authorised by a veterinarian (POM-V) | ||||||
Finilac 50 Oral Solution | Le Vet Beheer B.V. | GB National authorisation | Prescription only medicine to be authorised by a veterinarian (POM-V) | |||||||
Kelactin Oral SolutionVeyx-Pharma GmbH | GB National authorisation | Prescription only medicine to be authorised by a veterinarian (POM-V) | - | |||||||
|
Formulated as a solution for oral administration |
|
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
103 | F4 F = U.S. EPA ECOTOX database / U.S. EPA pesticide fate database / Miscellaneous WHO documents / FAO data, IPCS INCHEM data (US EPA Databases Related to Pesticide Risk Assessment ) 4 = Verified data |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known soil and groundwater metabolites |
None
Other known metabolites |
|
|
|
|
||||
---|---|---|---|---|---|---|---|
6-allyl-8b-carboxy-ergoline (Ref: FCE 21589) | acid derivative | Animal; Human (Urine) | ~0.3 | ||||
Ref: FCE 21904 | amide derivative | Animal | - | ||||
Ref: FCE 21590 | - | Animal (Urine) | Small quantity |
|
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
383 | R3 R = Peer reviewed scientific publications Rat3 = Unverified data of known source |
Moderate | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | - | - | |||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - |
|
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
383 | R3 R = Peer reviewed scientific publications Rat3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Rapidly and extensively metabolised in the liver and excreted mainly in faeces (rat data) | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hormonal agent May cause gastric problems May cause nausea, vomiting, abdominal cramps, anorexia, diarrhoea, and constipation Published data suggests Cabergoline is carcinogenic in mice and rats at high doses |
Handling issues |
|
|
|||
---|---|---|---|---|
|
No information available | |||
|
- | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
|
|
||
---|---|---|---|
|
cabergoline | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
cabergolina | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 18/05/2024 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |